Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY001-001 in Healthy Participants

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 09 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SPY 001 (Primary)
Indications Inflammatory bowel diseases
Focus Adverse reactions; First in man; Proof of concept
Sponsors Spyre Therapeutics

Most Recent Events

05 May 2025 According to a Spyre Therapeutics media release, company presented updated result data from this study at Digestive Disease Week (DDW) 2025, being held May 3-6, 2025, in San Diego, California.
26 Feb 2025 Planned End Date changed from 2 Aug 2025 to 5 May 2026.
26 Feb 2025 Planned primary completion date changed from 2 Aug 2025 to 5 May 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com